Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04VFJ
|
||||
Former ID |
DAP000793
|
||||
Drug Name |
Toremifene
|
||||
Synonyms |
Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Anticancer Agents
|
||||
Company |
Prostrakan Inc
|
||||
Structure |
Download2D MOL |
||||
Formula |
C26H28ClNO
|
||||
InChI |
InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
|
||||
InChIKey |
XFCLJVABOIYOMF-QPLCGJKRSA-N
|
||||
CAS Number |
CAS 89778-26-7
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
10366, 7980819, 10038137, 11528602, 12013627, 14757386, 29216214, 36055011, 46506087, 48416648, 53787422, 56352877, 57410179, 76883860, 92309038, 92718822, 93165674, 93166369, 93167220, 93626357, 96025304, 103628891, 111617870, 117870220, 124892293, 126621304, 126648750, 126669839, 127316634, 127316635, 127316636, 127316637, 127316638, 127316639, 127316640, 127316641, 127316642, 127316643, 127316644, 127316645, 127316646, 127316647, 127316648, 127316649, 127316650, 127316651, 127316652, 127316653, 127316654, 127316655
|
||||
ChEBI ID |
ChEBI:9635
|
||||
SuperDrug ATC ID |
L02BA02
|
||||
SuperDrug CAS ID |
cas=089778267
|
||||
Target and Pathway | |||||
Target(s) | Estrogen receptor | Target Info | Modulator | [537376] | |
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Signaling events mediated by HDAC Class II | |||||
Plasma membrane estrogen receptor signaling | |||||
LKB1 signaling events | |||||
Regulation of Telomerase | |||||
ATF-2 transcription factor network | |||||
AP-1 transcription factor network | |||||
FOXM1 transcription factor network | |||||
Validated nuclear estrogen receptor alpha network | |||||
Signaling mediated by p38-alpha and p38-beta | |||||
FOXA1 transcription factor network | |||||
References | |||||
Ref 467663 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4325). | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.